Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)
The purpose of this study is to evaluate the cholesterol lowering effectiveness and safety of two investigational drugs in patients with mixed hyperlipidemia (high cholesterol and high triglycerides).
Drug: MK0653, ezetimibe
Drug: Comparator: fenofibrate monotherapy
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Primary Purpose: Treatment
|Official Title:||Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia|
- Plasma LDL-C vs. fenofibrate for 12 weeks.
- All plasma lipid parameters vs. ezetimibe; all non-LDL lipid parameters vs. fenofibrate; safety and tolerability.
|Study Start Date:||January 2003|
|Primary Completion Date:||December 2003 (Final data collection date for primary outcome measure)|
The duration of treatment is 18 weeks.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00092560
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|